The campaign attracted strong support from private and professional investors across Europe, reflecting growing confidence in EVis’s hybrid RNA delivery platform and its potential to advance targeted gene therapies.

While gene therapies offer transformative potential for rare diseases and genetic disorders, the safe, precise, and scalable delivery of genetic material remains a critical bottleneck.

EVis Bioscience addresses this challenge through EVis NanoVector, a proprietary platform that enables the efficient loading of RNA into extracellular vesicles (EVs), leveraging a natural delivery system with strong potential for precision, safety, and scalability.

The company operates a hybrid business model combining platform licensing, R&D collaborations, and proprietary therapeutic development. EVis provides industry and academic partners with access to its technology through licensing and collaborative research programs, while simultaneously advancing its own therapeutic candidates for rare genetic diseases toward preclinical milestones.

Strategic Momentum

The successful raise builds on recent institutional validation, including the CHF 311,000 non-dilutive grant awarded by Innosuisse for an 18-month preclinical program in collaboration with the University of Zurich. Together, these milestones significantly reinforce EVis Bioscience’s scientific credibility and financial foundation.

Elita Montanari, CTO, acting CEO and co-founder of EVis Bioscience said: “The successful closure of our €740k pre-seed round on Capital Cell, reaching 105.5% of our target, represents a significant milestone for EVis Bioscience. We are grateful to our investors for their trust and support. Together with the backing of Innosuisse, we are now well positioned to advance our platform toward the next key stage of development.”

With the pre-seed round successfully completed, EVis Bioscience is positioned to advance its hybrid RNA delivery platform, expand its scientific team, strengthen preclinical development programs and prepare for future strategic financing rounds.

(startupticker.ch)